Zoetis Inc. (ZTS)
USD 167.01
(-2.21%)
USD 167.01
(-2.21%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.76 Billion USD | 2.48% |
| 2022 | 2.69 Billion USD | 1.05% |
| 2021 | 2.67 Billion USD | 13.67% |
| 2020 | 2.34 Billion USD | 4.4% |
| 2019 | 2.25 Billion USD | 10.67% |
| 2018 | 2.03 Billion USD | 12.51% |
| 2017 | 1.8 Billion USD | -0.99% |
| 2016 | 1.82 Billion USD | -6.75% |
| 2015 | 1.95 Billion USD | -6.77% |
| 2014 | 2.09 Billion USD | 1.3% |
| 2013 | 2.07 Billion USD | 6.64% |
| 2012 | 1.94 Billion USD | -0.31% |
| 2011 | 1.94 Billion USD | 5.29% |
| 2010 | 1.85 Billion USD | 26.18% |
| 2009 | 1.46 Billion USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 709 Million USD | -4.06% |
| 2024 Q3 | 732 Million USD | -2.66% |
| 2024 Q2 | 752 Million USD | 6.06% |
| 2023 Q1 | 684 Million USD | -1.87% |
| 2023 Q3 | 715 Million USD | -3.25% |
| 2023 Q4 | 739 Million USD | 3.36% |
| 2023 FY | 2.76 Billion USD | 2.48% |
| 2023 Q2 | 739 Million USD | 8.04% |
| 2022 Q3 | 672 Million USD | -4.14% |
| 2022 Q4 | 697 Million USD | 3.72% |
| 2022 Q1 | 628 Million USD | -18.55% |
| 2022 FY | 2.69 Billion USD | 1.05% |
| 2022 Q2 | 701 Million USD | 11.62% |
| 2021 Q3 | 676 Million USD | 3.05% |
| 2021 Q2 | 656 Million USD | 15.7% |
| 2021 Q1 | 567 Million USD | -18.18% |
| 2021 FY | 2.67 Billion USD | 13.67% |
| 2021 Q4 | 771 Million USD | 14.05% |
| 2020 Q3 | 576 Million USD | 5.88% |
| 2020 FY | 2.34 Billion USD | 4.4% |
| 2020 Q4 | 693 Million USD | 20.31% |
| 2020 Q1 | 536 Million USD | -16.77% |
| 2020 Q2 | 544 Million USD | 1.49% |
| 2019 Q4 | 644 Million USD | 19.04% |
| 2019 Q3 | 541 Million USD | -2.7% |
| 2019 FY | 2.25 Billion USD | 10.67% |
| 2019 Q1 | 509 Million USD | -12.84% |
| 2019 Q2 | 556 Million USD | 9.23% |
| 2018 Q3 | 507 Million USD | 4.75% |
| 2018 Q2 | 484 Million USD | 5.68% |
| 2018 Q1 | 458 Million USD | -7.29% |
| 2018 FY | 2.03 Billion USD | 12.51% |
| 2018 Q4 | 584 Million USD | 15.19% |
| 2017 Q4 | 494 Million USD | 10.51% |
| 2017 Q1 | 421 Million USD | -14.08% |
| 2017 FY | 1.8 Billion USD | -0.99% |
| 2017 Q2 | 445 Million USD | 5.7% |
| 2017 Q3 | 447 Million USD | 0.45% |
| 2016 Q4 | 490 Million USD | 7.46% |
| 2016 FY | 1.82 Billion USD | -6.75% |
| 2016 Q3 | 456 Million USD | 0.66% |
| 2016 Q2 | 453 Million USD | 6.34% |
| 2016 Q1 | 426 Million USD | -22.55% |
| 2015 FY | 1.95 Billion USD | -6.77% |
| 2015 Q4 | 550 Million USD | 14.58% |
| 2015 Q3 | 480 Million USD | 0.42% |
| 2015 Q2 | 478 Million USD | 6.46% |
| 2015 Q1 | 449 Million USD | -29.29% |
| 2014 Q2 | 503 Million USD | 9.83% |
| 2014 Q1 | 458 Million USD | -22.9% |
| 2014 FY | 2.09 Billion USD | 1.3% |
| 2014 Q4 | 635 Million USD | 26.24% |
| 2014 Q3 | 503 Million USD | 0.0% |
| 2013 Q1 | 462 Million USD | -21.69% |
| 2013 Q2 | 509 Million USD | 10.17% |
| 2013 FY | 2.07 Billion USD | 6.64% |
| 2013 Q3 | 507 Million USD | -0.39% |
| 2013 Q4 | 594 Million USD | 17.16% |
| 2012 Q2 | 452 Million USD | -0.88% |
| 2012 Q3 | 445 Million USD | -1.55% |
| 2012 Q4 | 590 Million USD | 32.58% |
| 2012 FY | 1.94 Billion USD | -0.31% |
| 2012 Q1 | 456 Million USD | -19.15% |
| 2011 Q4 | 564 Million USD | 25.33% |
| 2011 Q2 | 483 Million USD | 6.86% |
| 2011 FY | 1.94 Billion USD | 5.29% |
| 2011 Q1 | 452 Million USD | 0.0% |
| 2011 Q3 | 450 Million USD | -6.83% |
| 2010 FY | 1.85 Billion USD | 26.18% |
| 2009 FY | 1.46 Billion USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 616.19 Million USD | -348.725% |
| Bausch Health Companies Inc. | 5.23 Billion USD | 47.182% |
| Catalent, Inc. | 1.7 Billion USD | -62.456% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -164.847% |
| Elanco Animal Health Incorporated | 1.61 Billion USD | -71.526% |
| Perrigo Company plc | 1.52 Billion USD | -80.896% |
| Teva Pharmaceutical Industries Limited | 4.45 Billion USD | 37.879% |